文献速递前列腺癌

前列腺癌治疗新技术的成本:机器人辅助腹腔镜前列腺切除术、调强放疗与质子束治疗的成本及成本效果系统综述

Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.
PubMed 文献 · Eur Urol · 2017-03-31

该系统综述检索2001年1月至2016年7月Medline、Embase和Web of Science,比较机器人辅助根治性前列腺切除术(RARP)、调强放疗(IMRT)或质子束治疗与标准治疗的成本,分别纳入37、9、3项研究。新技术的治疗成本高于传统技术,但证据质量低且研究间不一致,成本差异的确切程度仍不明确。

要点

  • RARP对医院和支付方而言比耻骨后根治性前列腺切除术成本更高。
  • IMRT较三维适形放疗对支付方更昂贵,但增量成本效果比<$50 000/质量调整生命年时仍具成本效果。
  • 质子束治疗比IMRT更昂贵,因结局比较数据有限,其成本效果仍不明确。

核心结论

  • 与传统技术相比,新技术治疗成本更高,但证据质量低且研究间不一致,成本差异的确切程度仍不明确。
  • 若新技术能持续实现更好的结局,则可能具有成本效果。

研究设计与样本

  • 按PRISMA声明和方案进行系统综述,检索Medline、Embase和Web of Science于2001年1月至2016年7月发表的文献。
  • 比较RARP、IMRT或质子束治疗与标准治疗的成本,分别纳入37、9、3项研究。
  • 采用GRADE方法评价证据质量。

主要发现

  • RARP对医院和支付方而言比耻骨后根治性前列腺切除术成本更高,但在较长时限内实现最佳癌症和生存质量结局时,对支付方和社会可能具有中等成本优势。
  • IMRT从支付方角度看比三维适形放疗更昂贵,但以增量成本效果比<$50 000/质量调整生命年定义时也具有成本效果。
  • 质子束治疗比IMRT更昂贵,因结局比较数据有限,其成本效果仍不明确。
  • GRADE评价显示RARP和IMRT的证据质量低,质子束治疗的证据质量极低。

关键数值与推荐

  • IMRT的增量成本效果比<$50 000/质量调整生命年。
  • RARP和IMRT的证据质量低,质子束治疗的证据质量极低(GRADE)。

局限性

  • 证据质量低(RARP和IMRT)至极低(质子束治疗)。
  • 研究间存在不一致性,成本差异的确切程度仍不明确。
  • 结局改善(如癌症控制和治疗副作用)的不确定性妨碍了估计增加的成本是否值得。
  • 质子束治疗的比较结局数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Some of the high costs of robot-assisted radical prostatectomy (RARP), intensity-modulated radiotherapy (IMRT), and proton beam therapy may be offset by better outcomes or less resource use during the treatment episode. OBJECTIVE: To systematically review the literature to identify the key economic trade-offs implicit in a particular treatment choice for prostate cancer. EVIDENCE ACQUISITION: We systematically reviewed the literature according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement and protocol. We searched Medline, Embase, and Web of Science for articles published between January 2001 and July 2016, which compared the treatment costs of RARP, IMRT, or proton beam therapy to the standard treatment. We identified 37, nine, and three studies, respectively. EVIDENCE SYNTHESIS: RARP is costlier than radical retropubic prostatectomy for hospitals and payers. However, RARP has the potential for a moderate cost advantage for payers and society over a longer time horizon when optimal cancer and quality-of-life outcomes are achieved. IMRT is more expensive from a payer's perspective compared with three-dimensional conformal radiotherapy, but also more cost effective when defined by an incremental cost effectiveness ratio <$50 000 per quality-adjusted life year. Proton beam therapy is costlier than IMRT and its cost effectiveness remains unclear given the limited comparative data on outcomes. Using the Grades of Recommendation, Assessment, Development and Evaluation approach, the quality of evidence was low for RARP and IMRT, and very low for proton beam therapy. CONCLUSIONS: Treatment with new versus traditional technologies is costlier. However, given the low quality of evidence and the inconsistencies across studies, the precise difference in costs remains unclear. Attempts to estimate whether this increased cost is worth the expense are hampered by the uncertainty surrounding improvements in outcomes, such as cancer control and side effects of treatment. If the new technologies can consistently achieve better outcomes, then they may be cost effective. PATIENT SUMMARY: We review the cost and cost effectiveness of robot-assisted radical prostatectomy, intensity-modulated radiotherapy, and proton beam therapy in prostate cancer treatment. These technologies are costlier than their traditional counterparts. It remains unclear whether their use is associated with improved cure and reduced morbidity, and whether the increased cost is worth the expense.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Schroeck FR, Jacobs BL, Bhayani SB, et al. Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy. Eur Urol. 2017. PMID: 28366513. doi:10.1016/j.eururo.2017.03.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。